Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2006-09-05
2006-09-05
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C435S004000, C568S326000
Reexamination Certificate
active
07101917
ABSTRACT:
Methods of utilizing compounds of general formulas I and II as modulators and affinity labels of the MPTP complex are elucidated. Furthermore, methods for modulating the activity of the MPTP complex, methods for determining the presence of a component of the MPTP complex, and methods for identifying an active agent that modulates the activity of the MPTP complex, specifically methods for identifying an active agent that modulates the activity of the MPTP complex by interacting with the VDAC1 component are identified. Moreover, novel compounds of general formulas I and II are disclosed.
REFERENCES:
patent: 4241069 (1980-12-01), Buckler et al.
patent: 0 117 412 (1984-08-01), None
patent: 0 118 685 (1984-09-01), None
patent: 0 456 183 (1991-11-01), None
Cesura, AM et al., ‘The Voltage-dependent Anion Channel Is the Target for a New Class of Inhiitirs of the Mitochondrial Permeability Transition Pore’ J. Biol.Chem. 278(50) Dec. 12, 2003, pp. 49812-49818.
Andres M. Cesura, et al., The Journal of Biological Chemistry, vol. 278, No. 50, pp. 49812-49818 (2003).
Frederick E. Ward, et al., Journal of Medicinal Chemistry, vol. 24, No. 9, pp. 1073-1077 (1981).
Brouillet , E. et al; Proc. Nat'l Acad. Sci., (1995), 92(15) pp. 7105-7109.
Cassarino, D. et al: Biochim. Biophys. Acta., (1999), 1453, pp. 49-62.
Kroemer, G. et al; Nature Medicine, (2000) 6(5) pp. 513-519.
Vander Heiden, M.G., et al; Nature Cell Biol. (1999) 1(8) pp. E209-16.
Marzo, T. et al; Science, (1998) 281(5385) pp. 2027-2031.
Nicholls, D.G, and Budd, S.L., Physiol. Rev., (2000) 80(1) pp. 315-360.
Bernardi, P., Physiol. Rev. (1999) 79(4), pp. 1127-1155.
Bernardi, P. et al, Eur. J. Biochem. (1999) 264(3), pp. 687-701.
Wallace, D., Science (1999) 283(5407) pp. 1482-1488.
Crompton, M. , Biochem. J., (1999) 341, pp. 233-249.
Ichas, F. et al; Cell, (1997) 89, pp. 1145-1153.
Shimizu, S., et al, Nature, (1999) 399, 483-487.
Bernardi, P. et al, Trends Biochem. Sci. (2001) 26(2) pp. 112-117.
Dhainaut, A. et al., J. Med. Chem. (1992), vol. 35, pp. 2481-2496.
Costantini, P. et al., (1995), Toxicology vol. 99, pp. 77-88.
Sims, N. R., (1990), J. Neurochem. vol. 55, pp. 698-707.
Chernyak, B. V. & Bernardi, P., (1996), Eur. J. Biochem. vol. 238, pp. 623-630.
Hoek, J. B. et al., (1980), J. Biol. Chem. vol. 255, pp. 1458-1464.
Cesura Andrea
Pinard Emmanuel
Hoffmann-La Roche Inc.
Johnston George W.
Owens Amelia A.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
Mitochrondrial permeability transition pore affinity labels... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mitochrondrial permeability transition pore affinity labels..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mitochrondrial permeability transition pore affinity labels... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3588090